Cardiac dysfunction associated withtrastuzumab

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 619-629

  Smith, Karen Lisa ^a   Dang, Chau ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Cardiac toxicity; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARDIAC GLYCOSIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PATIENT MONITORING; REVIEW; RISK REDUCTION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GENETICS; HEART DISEASE; HEART STROKE VOLUME; METASTASIS; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; GENES, ERBB-2; HEART DISEASES; HUMANS; STROKE VOLUME;

EID: 33747471088     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.619     Document Type: Review

References (35)

1. SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
2. HENSON ES, HU X, GIBSON SB: Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin. Cancer Res. (2006) 12(3 Pt 1):845-853.
3. OCANA A, CRUZ JJ, PANDIELLA A: Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am. J. Clin. Oncol. (2006) 29(1):90-95.
4. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
5. MARTY M, COGNETTI F, MARANINCHI D et al.: Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. (2005) 23(19):4265-4274.
6. BASELGA J, TRIPATHY D, MENDELSOHN J et al.: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/ neu-overexpressing metastatic breast cancer. Semin. Oncol. (1999) 26(4 Suppl. 12):78-83.
7. VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20(3):719-726.
8. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17(9):2639-2648.
9. ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
10. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
11. SLAMON DJ, EIERMANN W, ROBERT NJ et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res. (2005) 94(Suppl. 1):S5.
12. SEIDMAN A, HUDIS C, PIERRI MK et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. (2002) 20(5):1215-1221.
13. JOENSUU H, KELLOKUMPU-LEHTINEN PL, BONO P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. (2006) 354(8):809-820.
14. KEEFE DL: Trastuzumab-associated cardiotoxicity. Cancer (2002) 95(7):1592-1600.
15. SPEYER J: Cardiac dysfunction in the trastuzumab clinical experience. J. Clin. Oncol. (2002) 20(5):1156-1157.
16. SEIDMAN AD, FORNIER MN, ESTEVA FJ et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. (2001) 19(10):2587-2595.
17. PEREZ EA, SUMAN VJ, DAVIDSON NE et al.: Interim cardiac safety analysis of NCCTG N9831 Intergroup Adjuvant Trastuzumab Trial. J. Clin. Oncol. (2005) 23(16 Suppl.):556.
18. TAN-CHIU E, YOTHERS G, ROMOND E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. (2005) 23(31):7811-7819.
19. PEREZ EA, SUMAN VJ, DAVIDSON NE et al.: Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Breast Cancer Res. (2005) 94(Suppl. 1):S96.
20. HUDIS C, CITRON ML, BERRY D et al.: Five year follow-up of INT C9741: dose dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res. (2005) 94(Suppl. 1):S20.
21. CITRON ML, BERRY DA, CIRRINCIONE C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. (2003) 21(8):1431-1439.
22. DANG C, SMITH K, FORNIER M et al.: Updated cardiac safety results of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER2/neu overexpressed/amplified breast cancer. J. Clin. Oncol. (2006) 24(18S Suppl.):582.
23. THE CRITERIA COMMITTEE OF THE NEW YORK HEART ASSOCIATION: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (7th edn). Little, Brown (Eds), Boston, USA (1973).
24. EWER MS, VOOLETICH MT, DURAND JB et al.: Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. (2005) 23(31):7820-7826.
25. SINGAL PK, ILISKOVIC N: Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. (1998) 339(13):900-905.
26. SAWYER DB, ZUPPINGER C, MILLER TA, EPPENBERGER HM, SUTER TM: Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation (2002) 105(13):1551-1554.
27. GARRATT AN, OZCELIK C, BIRCHMEIER C: ErbB2 pathways in heart and neural diseases. Trends Cardiovasc. Med. (2003) 13(2):80-86.
28. LEE KF, SIMON H, CHEN H et al.: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 378(6555):394-398.
29. CRONE SA, ZHAO YY, FAN L et al.: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. (2002) 8(5):459-465.
30. CHIEN KR: Herceptin and the heart-a molecular modifier of cardiac failure. N. Engl. J. Med. (2006) 354(8):789-790.
31. SPARANO JA, BROWN DL, WOLFF AC: Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf. (2002) 25(5):301-311.
32. PICHON MF, CVITKOVIC F, HACENE K et al.: Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo (2005) 19(3):567-576.
33. KANNEL WB, BELANGER AJ: Epidemiology of heart failure. Am. Heart J. (1991) 121(3 Pt 1):951-957.
34. TRIPATHY D, SEIDMAN A, KEEFE D et al.: Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin. Breast Cancer (2004) 5(4):293-298.
35. CHIA S, CLEMONS M, MARTIN LA et al.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multi-center Phase II trial. J. Clin. Oncol. (2006) 24(18):1-6.